Mar 25, 2024 8:00am EDT Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
Mar 12, 2024 9:15am EDT Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
Feb 15, 2024 9:00am EST Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
Jan 23, 2024 8:30am EST Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
Jan 08, 2024 8:30am EST Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
Dec 05, 2023 8:30am EST Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
Nov 30, 2023 9:00am EST Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
Nov 13, 2023 8:00am EST Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 09, 2023 9:00am EST Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
Nov 02, 2023 8:30am EDT Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023